Stop Atherosclerosis in Native Diabetics Study (SANDS): Baseline Characteristics of the
Randomized Cohort

Journal of Health Disparities Research and Practice
Volume 3

Issue 1

Article 3

© Center for Health Disparities Research, School of Public Health, University of Nevada, Las Vegas

2009

Stop Atherosclerosis in Native Diabetics Study (SANDS): Baseline
Characteristics of the Randomized Cohort
Angela Silverman , MedStar Research Institute
Chun-Chih J. Huang , MedStar Research Institute
Marie Russell , Phoenix Indian Medical Center
See next page for additional authors

Follow this and additional works at: https://digitalscholarship.unlv.edu/jhdrp
Part of the Cardiology Commons, Endocrinology, Diabetes, and Metabolism Commons, and the Public Health
Commons

Recommended Citation
Silverman, Angela; Huang, Chun-Chih J.; Russell, Marie; Mete, Mihriye; Roman, Mary J.; Stylianou, Mario;
Lee, Elisa T.; Yeh, Fawn; Fleg, Jerome; Wilson, Charlton; Henderson, Jeffrey A.; Weir, Matthew R.; Ratner,
Robert E.; and Howard, Barbara V. (2009) "Stop Atherosclerosis in Native Diabetics Study (SANDS):
Baseline Characteristics of the Randomized Cohort," Journal of Health Disparities Research and Practice:
Vol. 3 : Iss. 1 , Article 3.
Available at: https://digitalscholarship.unlv.edu/jhdrp/vol3/iss1/3

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV
with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself.
This Article has been accepted for inclusion in Journal of Health Disparities Research and Practice by an
authorized administrator of Digital Scholarship@UNLV. For more information, please contact
digitalscholarship@unlv.edu.

Stop Atherosclerosis in Native Diabetics Study (SANDS): Baseline Characteristics
of the Randomized Cohort
Abstract
Objectives: To present baseline characteristics of American Indians in the Stop Atherosclerosis in Native
Diabetics Study (SANDS) and compare them with population-based data from American Indians and
other ethnic groups. Design: 499 people with type 2 diabetes ≥ age 40, without known CVD, were
recruited for a randomized 3-year trial to evaluate treatment targets for LDL-C (70 vs. 100 mg/dL) and
systolic blood pressure (BP) (115 vs. 130 mmHg). Baseline evaluations included physical exam, collection
of blood and urine samples, and carotid ultrasound and echocardiographic measures. Results: Mean age
was 56 years; 66% were female. Average BMI was 33 kg/m2. Average duration of both hypertension and
diabetes was 10 years, average A1c was 8.0 %, and mean LDL-C was 104 mg/dL. Participants in the
conventional treatment group had slightly higher systolic BPs than participants in the aggressive
treatment group (133 mm Hg vs. 128 mm Hg, p < 0.002). Compared with the population-based cohorts of
the Strong Heart Study (SHS), NHANES, and the TRIAD registry, SANDS participants had similar values for
lipids, BP, and CRP, as well as degree of obesity, smoking rates, and renal function as indicated by
estimated glomerular filtration rate. Conclusions: The baseline characteristics of the SANDS cohort are
similar to those of a population-based sample of American Indian diabetic men and women and closely
resemble diabetic men and women of other ethnic groups. Results from this study can be used to identify
appropriate targets for LDL-C and BP lowering in diabetic American Indians and diabetic patients in other
ethnic groups.
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Abstract
Objectives: To present baseline characteristics of American Indians in the Stop Atherosclerosis in Native Diabetics Study (SANDS) and compare them with population-based
data from American Indians and other ethnic groups. Design: 499 people with type
2 diabetes ≥ age 40, without known CVD, were recruited for a randomized 3-year trial
to evaluate treatment targets for LDL-C (70 vs. 100 mg/dL) and systolic blood pressure
(BP) (115 vs. 130 mmHg). Baseline evaluations included physical exam, collection of
blood and urine samples, and carotid ultrasound and echocardiographic measures.
Results: Mean age was 56 years; 66% were female. Average BMI was 33 kg/m2. Average duration of both hypertension and diabetes was 10 years, average A1c was 8.0 %,
and mean LDL-C was 104 mg/dL. Participants in the conventional treatment group
had slightly higher systolic BPs than participants in the aggressive treatment group
(133 mm Hg vs. 128 mm Hg, p < 0.002). Compared with the population-based cohorts
of the Strong Heart Study (SHS), NHANES, and the TRIAD registry, SANDS participants
had similar values for lipids, BP, and CRP, as well as degree of obesity, smoking rates,
and renal function as indicated by estimated glomerular filtration rate. Conclusions:
The baseline characteristics of the SANDS cohort are similar to those of a populationbased sample of American Indian diabetic men and women and closely resemble
diabetic men and women of other ethnic groups. Results from this study can be used
to identify appropriate targets for LDL-C and BP lowering in diabetic American Indians
and diabetic patients in other ethnic groups.
Key words: lipids, blood pressure, carotid artery intimal medial thickness,
cardiovascular disease, American Indians
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INTRODUCTION
The aim of the Stop Atherosclerosis in Native Diabetics Study (SANDS)
is to determine optimum strategies for cardiovascular disease (CVD) risk
reduction in people with type 2 diabetes. SANDS is a randomized, open
label, 3-year trial comparing the effects of aggressive low-density lipoproteincholesterol (LDL-C) (goal < 70 mg/dL) and blood pressure (BP) (goal < 115/75
mm Hg) reduction with the standard treatment goals of < 100 mg/dL for
LDL-C and < 130/85 mm Hg for BP (1). The primary endpoint is a composite of
progression of atherosclerosis as measured by common carotid artery intimal
medial thickness (IMT) and clinical events. Secondary endpoints include
other carotid and cardiac ultrasonographic measures. The group treated to
lower targets had an improvement (decrease) in IMT, whereas the standard
treatment group had a worsening (increase) in IMT. There was also a greater
decrease in left ventricular mass index (LVMI) in the aggressive group. Few
CVD events occurred overall, with no intergroup difference (2).
SANDS was initiated because of the increasing incidence of CVD in
individuals with diabetes (1, 3 , 4) and the paucity of data on which to
make evidence-based recommendations for optimal treatment targets for
dyslipidemia and hypertension, established risk factors for CVD in diabetic
individuals ( 5, 6, 7). SANDS is being conducted in American Indians, a
population with high rates of diabetes and diabetes-related CVD (5). This is
the first large, randomized interventional trial among American Indians with
diabetes to assess CVD prevention strategies. The final sample, 499 men and
women without baseline CVD, was randomized over a 15-month period and
followed for 36 months, ending in July 2007.
This report describes the baseline characteristics of the 499 participants
who were randomized into SANDS. To assess the applicability of the trial
results to the American Indian population and other populations with
diabetes, we compared the baseline characteristics of SANDS participants
with three other groups. One was a population-based sample of American
Indians as described by Strong Heart Study (SHS) data. The second group
was representative of (8) the general U.S. population with diabetes as
described in the 1999-2004 National Health and Nutrition Examination
Survey (NHANES) data (9). NHANES 1999-2004 was designed to over sample
Mexican Americans, non-Hispanic blacks, and children and adolescents. The
final comparator group was the Translating Research Into Action for Diabetes
(TRIAD) (10) registry, which examined racial/ethnic and socioeconomic
variation in diabetes care in managed-care settings throughout the United
States. The TRIAD cohort included five ethnic groups, Hispanic, Black/
Non-Hispanic, White/Non-Hispanic, Asian/Pacific Islander, and Other. The
proportion of White/Non-Hispanic was more than twice than that of each of
the other groups.
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METHODS

Details of the study design and methods have been described elsewhere
(5). The target population consisted of American Indians in four clinical centers
in the United States: Lawton, OK; Phoenix, AZ; Chinle, AZ; and Rapid City, SD.
Recruitment was initiated in May 2003. Each center developed communityspecific recruitment plans that included informational mailings, community
presentations, and referrals from local providers. Informed consent was
obtained from all participants before screening, and the study was approved
by the institutional review boards (IRBs) of all participating institutions and
the Indian Health Service and by all participating tribal communities. At least
one screening visit and a separate randomization visit were required to assess
and confirm eligibility, complete randomization, and collect baseline data.
Sonogram eligibility, defined as having adequate images for measurement of
intimal-medial thickness, was required prior to randomization.
Eligibility criteria included age ≥ 40 years, type 2 diabetes documented by
medical record, LDL-C > 100 mg/dL, and systolic BP > 130/85 mm Hg. Because
lipid and BP measurements are variable, up to four screening visits within a
3-month period were allowed to confirm eligibility. Those taking BP or lipid
lowering medications with elevations in systolic BP or LDL-C documented in
the medical record were admitted at the discretion of the field physician if it
was felt that the participant could safely adhere to the study algorithms. Major
exclusions included medical conditions that would preclude participation in a
3-year trial or a history of serious adverse effects from the major study drugs.
Participants with prevalent CVD were randomized during the early months
of recruitment. After release of the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) (11) guidelines, which recommended an
LDL-C treatment goal of 70 mg/dL for patients with CVD and other risk factors,
such as diabetes, the steering committee determined, and the Data and Safety
Monitoring Board (DSMB) concurred, that all participants with clinical CVD
would be treated to an LDL-C goal of 70 mg/dL and removed from the primary
analysis. Randomization concluded in September 2004 with 548 participants,
499 of whom had no prevalent CVD.
Physical Measures
Anthropometric measurements were performed using standardized
methods, with the participant fasting and having an empty bladder, and
included height, waist circumference measured to the nearest quarter inch and
weight measured to the nearest tenth pound. Sitting BP was measured on the
right brachial artery, and the mean of the second and third measurements was
used. Behavioral risk factors were assessed using standardized intervieweradministered questionnaires, and medical history and medication assessment
were performed by both interview and chart review. Clinic staff were certified
in all measurements and interviews, and quality control was maintained
through periodic monitoring of duplicate measures and data entry.
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Laboratory Measures
Blood and urine samples were collected after a 12-hr overnight fast,
and plasma and serum samples were shipped to the core lab (Penn Medical
Lab). All samples were shipped and stored at -70º C. Baseline measurements
included fasting glucose, complete metabolic profile, A1c, C-reactive protein
(CRP), lipid profile, and urine for creatinine, albumin, and sodium. Details of
assay standardization and quality control have been described elsewhere (5).
Carotid Ultrasound and Echocardiographic Measures
Carotid ultrasound and echocardiographic studies were obtained at
baseline before randomization. All ultrasound studies were performed using
standardized protocols developed and refined by the Ultrasound Reading
Center at Weill Medical College of Cornell University in New York (12). Skilled
physician-readers blinded to participant characteristics interpreted all
studies. Extensive B-mode imaging from multiple angles was performed to
determine the presence and location of plaque, defined as the presence of
focal protrusion at least 50% greater than the surrounding wall thickness
(13). Pulsed Doppler sampling of the common carotid artery (CCA), carotid
bifurcation, and internal and external carotid arteries was performed
to quantify the presence of significant obstruction (14). The procedure
was repeated on the contralateral artery. Plaque severity was graded as
obstructive (> 50% occlusion based on peak Doppler systolic velocity) or
non-obstructive. A plaque score (0-8) was determined based on the number
of segments of each carotid artery containing plaque (15). IMT of the far wall
of the distal left and right common carotid arteries 1-2 cm proximal to the
carotid bifurcation was measured at end diastole using a semi-automated
system, which averages 100 individual measurements over a 1-cm length of
the vessel. Right and left IMTs were averaged. Vascular mass of the arteries
was calculated as cross-sectional area, using end-diastolic diameter and wall
thickness.
Echocardiographic performance and interpretation adhered to published
methods (16, 17). Briefly, participants were examined in a partial left
decubitus position, using phased-array echocardiographs. Attention was paid
to correct orientation of imaging planes. The entire study was recorded on
videotape and sent to the Reading Center for interpretation. Left ventricular
end-diastolic and end-systolic wall thicknesses and diameters were measured
from parasternal images using American Society of Echocardiography
recommendations (18 ,19). Derived variables from these linear measurements
included assessment of left ventricular structure (mass and relative wall
thickness) and function (fractional shortening and ejection fraction [EF]). The
location and severity of segmental wall motion abnormalities were noted.
Data Management and Analysis
Data collected in the field center were entered by staff certified in using
a web-based system developed by the Data Coordinating Center (DCC).
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Laboratory and ultrasound data were transmitted electronically to the
DCC. The central database was maintained using standardized methods for
ensuring security and verifying accuracy and consistency.
This paper presents descriptive statistics for all variables of interest in the
form of means and standard deviations for continuous variables and number
of observations and percentages for categorical variables. In addition,
two-sample comparisons are provided to examine if there are significant
differences between the conventional and aggressive groups. Differences in
the means are tested using two-sample t-tests for means, and differences in
the proportions are tested using two-sample tests of proportions. Positively
skewed variables such as carotid measures, CRP, and triglyceride levels
are log-transformed prior to the application of the two-sample tests, and
geometric means or medians and inter-quartile ranges are presented for
these variables.

RESULTS
Demographic and Physical Characteristics
Of the 1097 men and women who underwent screening, 548 were
randomized into the trial. Forty-nine with documented CVD at baseline
were excluded based on the recommendation of the DSMB, leaving 499
participants (Table 1). Mean age was 56 years; 66% were women. A large
proportion (66%) was obese, with an average BMI of 33 kg/m2 in both
men and women (Table 1). Average duration of diabetes was 10 years. No
significant differences were found in baseline characteristics between the
treatment groups, other than slightly higher systolic BP in the conventional
treatment group (133 vs. 128 mm Hg, p < .002) and age (56.9 years vs. 55.3
years, p = 0.05). No significant differences were found between the groups
in baseline laboratory measures (Table 2). Serum LDL-C averaged 104 mg/
dL in both groups. A1c averaged 8.0 %. Less than 1% had macroalbuminuria,
defined as urine albumin/creatinine > 300 mg/g.
Baseline Medications
Baseline medication usage is listed in Table 3. Seventy-three percent
of the cohort took anti-hypertensive medications at baseline; angiotensin
converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) were
used by 64%, with no other single agent used by more than 21%. Only 38%
of participants were taking a lipid-lowering agent at baseline. Statins were
the most commonly used lipid-lowering agents (34%), while fibrates were
used by 5%. Ezetimibe was not readily available at the time of randomization.
Sixteen percent of participants took no anti-diabetic agent at baseline. Most
participants took oral medications only for diabetes (61%), with 6% using
insulin only and 17% using both.
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Cardiovascular Measures
Carotid IMT and mass and presence and extent of carotid atherosclerosis
(Table 4) were similar between the two groups. Echocardiographic measures
of LV structure and function were also similar between the groups.

Table 1. Baseline Characteristics of Participants Without CVD at
Baseline
Analysis Variables
Participants (N)
Female

Conventional

Aggressive

247

252

160 (64.8)

167 (66.3)

P-value*
.73

Age at randomization (yrs)

56.9 (8.9)

55.3 (9.3)

.05

SBP (mm Hg)

133 (16.6)

128 (14.9)

.002

DBP (mm Hg)

76 (10.4)

74.4 (10.3)

.04

Duration of hypertension (yrs)

10.4 (8.5)

9.4 (8.2)

.26

Duration of diabetes (yrs)

9.6 (8.1)

9.8 (7.6)

.82

BMI (kg/m ) Men

32.8 (5.5)

33.5 (6.4)

.44

BMI (kg/m ) Women

33.4 (6.5)

33.5 (6.7)

.88

BMI (kg/m ) < 30

75 (30.5)

80 (31.8)

.74

2
2
2

BMI (kg/m ) > 30

172 (69.5)

172 (68.2)

.74

Total daily calories (Kcal)

2098 (1547)

1880 (1190)

.15

Waist circumference (cm) Men

111.4 (13.4)

113.1 (16.1)

.45

Waist circumference (cm) Women

109.3 (14.3)

108.8 (14.9)

.74

244

243

Never

123 (51)

109 (45)

.20

Current

48 (20)

54 (22)

.58

Former

73 (30)

80 (33)

.60

2

Smoking status (N)

SBP = systolic blood pressure; DBP = diastolic blood pressure. Percentages
may not add up to 100 because of rounding. Data presented in this table
are means with standard deviations in parentheses for continuous variables
and N and percentages for categorical variables.
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Table 2. Baseline Laboratory Values by Treatment Group
Analysis Variables
Conventional
Aggressive

P-value*

Fasting glucose (mg/dL) (SD)

156.5 (71.1)

159.3 (69.3)

.66

CRP* (95% CI)

2.84 (2.433.31)

2.66 (2.273.11)

.56

Serum creatinine (mg/dL) (SD)

0.85 (0.2)

0.83 (0.2)

.34

Cholesterol (mg/dL) (SD)
Total

185 (33)

184 (33)

.56

LDL
HDL
Non-HDL

104 (29)
46 (12)
140 (32)

104 (30)
46 (13)
138 (32)

.95
.90
0.50

Triglycerides (mg/dL)* (95% CI)

168 (159-177)

158 (149-167)

.10

.09

Microalbumin/creatinine ratio (urine)
(N) % normal (< 30 mg/g)

(139) 87

(148) 94

(N) % with micro-albuminuria
(30-300 mg/g)

(19) 12

(14) 5

Mean (SD)
(N) % < 60 ml/min

88.2 (23.3)
(18) 11.1

90.9 (24.1)
(3) 9.3

.21
.51

Urinary sodium (mmol/L) (SD)

99.4 (50.6)

98.3 (48.2)

.84

Estimated GFR (MDRD)

CRP = C-reactive protein; GFR = glomerular filtration rate; MDRD = Modification of Diet
in Renal Disease. *Geometric mean with 95% confidence interval in parenthesis. Twosample comparison t-tests are calculated based on log-transformed variables.

Comparison with Population-Based Data
Compared with the population-based cohort of American Indians in
the SHS (7), SANDS participants had similar values for lipids, BP, and CRP, as
well as degree of obesity, smoking rates, and renal function as estimated
by glomerular filtration rate (GFR) (Table 5). The SANDS cohort was slightly
younger, with a shorter duration of diabetes, but average A1c was similar.
Compared with men and women with diabetes in NHANES (9), SANDS
participants were slightly younger with slightly shorter diabetes duration
and slightly higher A1cs. BPs in the two groups were similar. LDL-C, high
density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were lower
among the SANDS participants, but smoking rates were similar. Compared
with participants in TRIAD, SANDS participants were somewhat younger, more
likely to be female, and had somewhat lower mean systolic BP and LDL-C.
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Table 3. Baseline Medication Use
Conventional (%)
N
242
Anti-hypertensive
ACE inhibitor/ARB
155 (63)
Thiazide diuretic
29 (12)
Beta blocker
24 (10)
Calcium blocker
48 (20)
Other anti HTN rx
56 (23)
Any
185 (75)
Lipid lowering
Statin
90 (37)
Fibrate
13 (5)
Ezetimibe
2 (0.8)
Any
101 (41)
Diabetes
Insulin only
12 (5)
Oral agent only
145 (59)
Both (oral and insulin)
38 (15)
Lifestyle only
52 (21)
Aspirin
89 (36)

Aggressive (%)
252

P-value*

163 (65)
20 (8)
19 (8)
43 (17)
50 (20)
179 (71)

.65
.15
.38
.48
.43
.28

80 (32)
12 (5)
1 (0.4)
90 (36)

.26
.48
.49
.23

18 (7)
158 (63)
48 (19)
28 (11)
77 (31)

.28
.62
.28
.003
.18

Entries are numbers of observations; percentages are in parentheses.

Table 4. Echocardiographic and Carotid Measures
Conventional

Aggressive

P-value

.78 (.68-.87)

.78(.69-.90)

.48**

16.7 (14.2-19.4)

16.6(13.9-19.5)

.99**

Plaque (%) ***
Plaque score
LV ejection fraction (%)
LV mass (g)

76
2(1-3)
59.8 (5.8)
156.1 (38.3)

75
2 (0-3)
60.5 (5.7)
156.7 (38.3)

.64
.89**
.19
.86

LV mass index (g/m2.7)

40.6 (8.5)

41.2 (9.5)

.43

% LVH men, > 49.2/m ***

14

22

.15

% LVH women ,
> 46.7 g/m2.7 ***

23

30

.14

CCA IMT (mm) *
CCA mass (mm )*
2

2.7

*Medians and inter-quartile ranges (observations between 25th and 75th percentile)
are provided for positively skewed variables. **p-values represent the results of
two-sample means tests applied to the log-transformed continuous variables. The
descriptive statistics for these continuous variables are based on actual values.
*** indicates categorical variables. The entries in the means columns for these
variables are percentages within each group. P-values are based on two-sample tests
of proportions.
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Table 5. Comparison of SANDS Cohort with Other Diabetic Cohorts
SHS
NHANES*
SANDS
(with
(1999TRIAD**
diabetes)
2004)
N
499
1733
1549
3707
1838
Male (%)
172 (34)
590 (34)
759 (49)
(50)
1869
Female (%)
327 (66)
1143 (66)
790 (51)
(50)
Age (yrs) (SD)
56 (9.0)
63 (7)
59 (0.5)
62 (13)
BMI (kg/m2)
Men (SD)
Women (SD)

33.1 (6.0)
33.5 (6.6)

31.4
33.3

Men and women

33.3

32.7

HTN duration (yrs)

9.9 (8.3)

8.0

SBP (mmHg)

130.4 (15.9)

132 (20.2)

132 (0.8)

DBP (mmHg)
Diabetes duration
(yrs)
A1c (%) (SD)
Total cholesterol
(mg/dL) (SD)
LDL-C (mg/dL) (SD)

75.3 (10.4)

75 (29.7)

69 (0.72)

9.7 (7.8)

15.7 (12.2)

12.0 (0.5)

8.0 (1.8)

8.1 (1.9)

7.5 (0.2)

7.8 (1.7)

184

182 (39)

205(2)

196 (43)

104

110 (32)

115 (2)

110 (33)

HDL-C (mg/dL) (SD)
Non-HDL-C (mg/dL)
(SD)

46

40 (12)

47 (1)

46 (13)

139 (32)

142 (39)

196 (9)

151 (42)

NA

220
(187)
75.8
(25.2)
49

TG (mg/dL) (SD)
eGFR % < 60 ml/min
(SD)
Smoking (% ever)
Mean IMT (mm)
Mean CCA mass
(mm2)
Plaque (%)
Plaque score (n)
LVMI (g/m2.7)

163 (geo
mean)
89.6 (23.7)
10%
52.3
0.80 ± 0.18

84.22 (28.6)
16%
58.8
0.75 ± 0.16

17.3 ± 4.8

16.5 ± 4.5

76
1.8 ± 1.6
40.9 (9.0)

67
1.7 ± 1.7
40.4 (10.0)

31.8

162 (122)

53.2

31.5
136
(19.0)
76 (11.0)

*The NHANES cohort excluded people who were pregnant or on dialysis. **The TRIAD
cohort was white, non-Hispanic. HTN = hypertension; SBP = systolic blood pressure;
DBP = diastolic blood pressure; LDL-C = low-density lipoprotein-cholesterol; HDL-C =
high-density lipoprotein-cholesterol; TG = triglycerides; eGFR = estimated glomerular
filtration rate; NA = not applicable.
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DISCUSSION
Baseline BP levels in the SANDS participants were within the normal
range, probably due to the use of antihypertension medications by over 70%.
Of note, average BP levels in American Indians are lower than those in other
U.S. populations and, even in those with diabetes, stage III or IV hypertension
is rare (20). Nevertheless, BP is a strong predictor of CVD events in American
Indians (20), even in those with pre-hypertension (21). Thus, it was postulated
that risk would be considerably reduced with the intensive intervention.
Lipid levels are also low in this cohort, with a mean LDL-C of 104 mg/dL.
Only 38% were taking statins or other hypolipidemic medication at baseline.
LDL-C levels are lower among American Indians than in the general U.S.
population and are slightly lower in diabetic than in non-diabetic individuals
(22). Despite a relatively low mean level, LDL-C is the strongest lipid predictor
of CVD in American Indians with diabetes; a 10-mg/dL increase in LDL-C is
associated with a 12% increase in CVD risk (23). These data indicate that
LDL-C has a particularly strong impact on CVD in this population, suggesting
that the lower therapeutic target will be effective.
Carotid artery IMT is a widely accepted surrogate marker for
atherosclerosis and is strongly associated with major CVD risk factors (24)
and prevalent and incident CVD (25). Diabetes is associated with increased
IMT (26,27 ). In other diabetic populations, carotid IMT predicted CVD and
correlated with CVD risk factors, such as diabetes (28). Plaque and plaque
score are independent predictors of incident CVD events in American
Indians without pre-existing CVD. All four measures of sub-clinical carotid
atherosclerosis in SANDS were slightly higher compared with the diabetic SHS
participants studied a mean of 6 years earlier (Table 5), suggesting that subclinical disease among American Indians may be increasing, despite lower
mean LDL-C and BP levels. Thus, differences in these surrogate measures
in the aggressive and conventional therapy groups at the conclusion of the
study may predict differences in the occurrence of CVD events in the two
groups
Left ventricular hypertrophy (LVH) is a strong, independent risk indicator
for CVD events. Reversal of LVH has prognostic benefit, independent
of therapy and BP (28). Diabetes has been shown to be independently
associated with greater absolute and relative LV wall thicknesses (but
not larger chamber size) and with higher absolute and indexed LV mass
independent of all confounders (17). Absolute LV mass, or LV mass indexed
for measures of body size, was virtually identical in SANDS (41.0 gm/
m2.7, SD 9.2) and SHS participants with diabetes (40.4 gm/m2.7, SD 10.0)
(29). Echocardiographic structural and functional abnormalities are highly
prevalent among American Indians with diabetes and appear to be predictors
of clinical CVD events. In a regression analysis that considered other
predictors of mortality, cardiovascular death in diabetic SHS participants was
most strongly predicted by higher LV mass/height2.7 (p = 0.0001) (30). When

Stop Atherosclerosis in Native Diabetics Study • Silverman et al.

39

analyses were restricted to participants with diabetes, all-cause mortality,
cardiovascular death, and nonfatal cardiovascular events were all more
common in those with LV hypertrophy (28). Thus, SANDS will have the added
benefit of determining whether several abnormalities in cardiac structure and
function also improve with risk-factor modification, an issue not previously
addressed in any diabetes trials.
The SANDS cohort consisted of trial volunteers and thus is subject
to the healthy volunteer bias in clinical trial participants. Additionally,
individuals with CVD and renal failure were excluded from SANDS but not
SHS. Thus, it was important to determine to what extent the SANDS cohort
is representative of other diabetic groups. The baseline characteristics of the
SANDS cohort are similar to those of the American Indian diabetic population
from the Strong Heart Study and also resemble diabetic men and women
of other ethnic groups. Although blood pressure and LDL-C in the SANDS
cohort are not high, the carotid ultrasound and echocardiographic findings
show much evidence of preclinical disease.
Traditional goals for blood pressure (< 130/80 mmHg) and LDL-C (<
100 mg/dL) for high-risk patients may be inadequate to reduce CVD risk in
American Indians and other diabetic populations at high risk for CVD. The
data obtained in this study have provided evidence to define therapeutic
prevention strategies that can reverse the alarming increase in CVD among
American Indians with diabetes and will guide treatment strategies for
diabetic individuals from all U.S. ethnic groups and in other countries where
diabetes rates are rising.

REFERENCES
1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for
cardiovascular disease: The Framingham Study. Diabetes Care 1979;2:120126.
2. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA,
Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A,
Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F,
Zhu J. Effect of lower targets for blood pressure and LDL cholesterol on
atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008 Apr
9;299(14):1678-89
3. Kleinman JC, Donahue RP, Harris MI, et al. Mortality among diabetics in a
national sample. Am J EpidemioI 1988;128:389-401.
4. Butler WJ, Ostrander LD, Can11an WJ, et al. Mortality from coronary heart
disease in the Tecumseh Study: Long-term effect of diabetes mellitus,
glucose tolerance and other risk factors. Am J Epidemiol 1985;121:541-547.
5. Russell, M. Examination of lower targets for low-density lipoprotein
cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in
Native Diabetics Study (SANDS). Am Heart J 2006; Nov;152(5):867-875.

40

Journal of Health Disparities Research and Practice • Vol. 3, No. 1 • Spring 2009

6. Howard BV. Macrovascular complications of diabetes mellitus. In: Diabetes
Mellitus, Eds. LeRoith D, Taylor SI and Olefs, JM (Lippincott-Raven,
Philadelphia, 1996), pp. 792-797.
7. Klein R. Kelly West Lecture 1994: Hyperglycemia and microvascular and
macrovascular disease in diabetes. Diabetes Care 1995;18:258-268.
8. Howard BV, Lee ET, Cowan LD, et al. Rising tide of cardiovascular disease in
American Indians: The Strong Heart Study. Circulation 1999;99:2389-2395.
9. NHANES (1999-2004). (http://www.cdc.gov/nchs/nhanes.htm)
10. Brown A, Gregg E. Race, ethnicity, socioeconomic position, and quality
of care for adults with diabetes enrolled in managed care. Diabetes Care
2005;28:2864-2869.
11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical
trials for the National Cholesterol Education Program Adult Treatment
Panel III guidelines. Circulation 2004;110:227-239.
12. Devereux RB, Roman MJ, Evaluation of cardiac and vascular structure
by echocardiography and other noninvasive techniques. In: Laragh
JH, Brenner BM, editors. Hypertension: Pathophysiology, diagnosis,
management. 2nd ed. New York: Raven Press; 1995, pp 1969-85.
13. O’Leary DH, Polak JF, Kronmal RA, et al. Corotid–artery intimal and media
thickness as a risk factor for myocardial infarction and stroke in older
adults. N Engl J Med 1999;340:14-22.
14. Zwiebel WJ. Doppler evaluation of carotid stenosis. In Introduction to
Vascular Sonography (3rd ed.). Philadelphia: W.B. Saunders: 1992, pp.123132.
15. Pini R, Cavallini C, Bencini F, et al. Cardiovascular remodeling is greater
in isolated systolic hypertension than in diastoci hypertension: The
Insuffucuenza Cardiaca gegli Anzianai Residenti (ICARe) a Dicomano Study.
J Am Coll Cardiolol 2002;40:1283-9.
16. Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure
by echocardiography and other noninvasive techniques. In Laragh
JH, Brenner BM (Eds): Hypertension: Pathophysiology, Diagnosis,
Management, 2nd ed. New York: Raven Press: 1995. pp 1969-1985.
17. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac
structure and function: The Strong Heart Study. Circulation 2000;101:22712276.
18. Schiller NB, Shah PM, Crawford M, et al. Recommendations for
quantitation of the left ventricle by two-dimensional echocardiography. J
Amer Soc Echocardiogr 1989;2:358-367.
19. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for
evaluation of the severity of native valvular regurgitation with twodimensional and Doppler echocardiography. J Am Soc Echocardiogr
2003;16:777-802.

Stop Atherosclerosis in Native Diabetics Study • Silverman et al.

41

20. Howard BV, Lee ET, Yeh JL, Go O, Fabsitz RR, Devereux RB, Welty TK.
Hypertension in adult American Indians: The Strong Heart Study.
Hypertension 1996;28:256-264.
21. Zhang Y, Lee ET, Devereux RB, Yeh J, Best L, Fabsitz R, Howard BV.
Prehypertension, diabetes and cardiovascular disease risk in a populationbased sample: the Strong Heart Study. Hypertension 2006;47;410-414.
22. Howard BV, Lee ET, Cowan LD, Fabsitz RR, Howard WJ, Oopik AJ, Robbins
DC, Savage PJ, Yeh JL, Welty TK. Coronary heart disease prevalence and its
relation to risk factors in American Indians: the Strong Heart Study. Am. J.
Epidemiol 1995 142:254-268.
23. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux
RB, Cowan LD, Gray RS, Welty TK, Go OT, Howard WJ. LDL cholesterol
as a strong predictor of coronary heart disease in diabetic individuals
with insulin resistance and low LDL. Arterioscler Thromb Vasc Biol
2000;20:830-5.
24. Heiss G, Wharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C, and
the ARIC Investigators. Case-control analysis of atherosclerosis and
established risk factors. Am J Epidemiol 1991; 134:250-256.
25. Roman MJ, Naqvi TZ, Gardin JM, Gerhard-Herman M, Jaff M, Mohler E.
Clinical application of noninvasive vascular ultrasound in cardiovascular
risk stratification: a report from the American Society of Echocardiography
and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr
2006;19:943-954.
26. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Barnes RW, Cram KB,
Hutchinson RG. Relation of carotid artery wall thickness to diabetes
mellitus, fasting glucose and insulin, body size and physical activity. Stroke
1994;25:66-73.
27. Wagenknecht LE, D’Agostino RJr, Savage PJ, O’Leary DH, Saad MF, Haffner
SM. Duration of diabetes and carotid wall thickness: the Insulin Resistance
Atherosclerosis Study (IRAS). Stroke 1997; 28:999-1005.
28. Devereux RB, Wachtell K, Gerdts E, et al. Regression of left ventricular
hypertrophy : treatment effects and prognostic implications in the LIFE
trial. J Hypertension 2002:20 (suppl 4):S4.
29. Bella JN, Devereux RB, Roman MJ, Pamierei et al. Separate and joint
effects of systemic hypertension and diabetes mellitus on left ventricular
structure and function in American Indians: The Strong Heart Study. Am J
Cardiol 2001;87:1260-1265.
30. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz RR, Lee ET, Welty TK, Howard
BV, Devereux RB. Cardiovascular disease and prognosis in adults with
glucose disorders: The Strong Heart Study. J Am Coll Cardiol 2000;35:263A.

42

Journal of Health Disparities Research and Practice • Vol. 3, No. 1 • Spring 2009

ACKNOWLEDGEMENTS
This work was supported by grant U01-HL067031 from the National
Heart, Lung, and Blood Institute. We thank the SANDS participants
and participating tribal communities for the extraordinary cooperation
and involvement that made this study possible. We thank the TRIAD
coinvestigators and staff for their important contributions. We gratefully
acknowledge the editorial assistance of Rachel Schaperow, MedStar Research
Institute, Hyattsville, MD. The views expressed in this paper are those of the
authors and do not necessarily reflect those of the Indian Health Service.

Angela Silverman, MSN, CANP; MedStar Research Institute,
Hyattsville, MD

Chun-Chih J. Huang, PhD; MedStar Research Institute, Hyattsville, MD,
Marie Russell, MD; Phoenix Indian Medical Center, Phoenix, AZ
Mihriye Mete, PhD; MedStar Research Institute, Hyattsville, MD
Mary J. Roman, MD; Weill Medical College of Cornell University,
New York, NY

Mario Stylianou, PhD; National Heart, Lung, and Blood Institute,
Bethesda, MD

Elisa T. Lee, PhD; University of Oklahoma Health Sciences Center,
Oklahoma City, OK

Fawn Yeh, PhD; University of Oklahoma Health Sciences Center,
Oklahoma City, OK

Jerome Fleg, MD; National Heart, Lung, and Blood Institute,
Bethesda, MD

Charlton Wilson, MD; Phoenix Indian Medical Center, Phoenix, AZ
Jeffrey A. Henderson, MD; Black Hills Center for American Indian
Health, Rapid City, SD

Matthew R. Weir, MD; University of Maryland School of Medicine,
Baltimore, MD

Robert E. Ratner, MD; MedStar Research Institute, Hyattsville, MD
Barbara V. Howard, PhD; MedStar Research Institute, Hyattsville, MD

